- Home
- NNBR vs ADAP Comparison
NNBR vs ADAP Comparison
Compare NNBR & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNBR
- ADAP
- Stock Information
- Founded
- NNBR 1980
- ADAP 2008
- Country
- NNBR United States
- ADAP United Kingdom
- Employees
- NNBR N/A
- ADAP N/A
- Industry
- NNBR Industrial Machinery/Components
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- NNBR Industrials
- ADAP Health Care
- Exchange
- NNBR Nasdaq
- ADAP Nasdaq
- Market Cap
- NNBR 111.0M
- ADAP 75.5M
- IPO Year
- NNBR 1994
- ADAP 2015
- Fundamental
- Price
- NNBR $2.20
- ADAP $0.24
- Analyst Decision
- NNBR
- ADAP Buy
- Analyst Count
- NNBR 0
- ADAP 6
- Target Price
- NNBR N/A
- ADAP $1.35
- AVG Volume (30 Days)
- NNBR 549.4K
- ADAP 672.4K
- Earning Date
- NNBR 08-06-2025
- ADAP 08-11-2025
- Dividend Yield
- NNBR N/A
- ADAP N/A
- EPS Growth
- NNBR N/A
- ADAP N/A
- EPS
- NNBR N/A
- ADAP N/A
- Revenue
- NNBR $448,780,000.00
- ADAP $179,639,000.00
- Revenue This Year
- NNBR N/A
- ADAP N/A
- Revenue Next Year
- NNBR $4.96
- ADAP $35.48
- P/E Ratio
- NNBR N/A
- ADAP N/A
- Revenue Growth
- NNBR N/A
- ADAP 878.53
- 52 Week Low
- NNBR $1.58
- ADAP $0.20
- 52 Week High
- NNBR $4.67
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- NNBR 51.75
- ADAP 37.80
- Support Level
- NNBR $1.80
- ADAP $0.23
- Resistance Level
- NNBR $2.13
- ADAP $0.26
- Average True Range (ATR)
- NNBR 0.14
- ADAP 0.02
- MACD
- NNBR 0.00
- ADAP -0.00
- Stochastic Oscillator
- NNBR 65.85
- ADAP 23.04
About NNBR NN Inc.
NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.